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INTRODUCTION
Epithelial ovarian cancer is one of the most deadly cancers with an overall 5-year survival of only 30-40%. Increasing evidence suggests that obesity is a significant risk factor for ovarian cancer and is associated with worse outcomes for this disease (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Less is known of the impact of the timing of the obesity exposure, but some epidemiological studies suggest that adolescent exposure to obesity bears the greatest increased risk for ovarian cancer development (12, 15) . We hypothesize that the metabolic and endocrine effects of obesity play a role in the carcinogenesis of ovarian cancer and invariably lead to biologically distinct cancers than those that arise in leaner women, possibly through aberrant modulation of mTOR signaling in an obesity-specific mechanism. An understanding of the relationship between obesity across the lifespan of a woman, and mTOR activation in ovarian cancer pathogenesis has yet to be explored and makes this proposal novel. This translational proposal will address this gap in knowledge by investigating the impact of the timing of the obesity exposure in vivo and in vitro using a novel serous ovarian tumor murine model and in ovarian cancer tumors from obese and non-obese women via interrogation of The Cancer Genome Atlas (TCGA) Project database. We postulate that in utero and adolescent exposure to obesity will increase vulnerability to ovarian cancer, and this will be manifested in obesity-specific mTOR hyperactivation and its downstream effects on enhanced proliferation and an advantageous metabolic profile. (KpB) mice exposed to a high fat diet at different time points across the lifespan, including in utero, adolescence and adulthood.
We have previously described a unique serous ovarian cancer mouse model that specifically and somatically deletes the tumor suppressor genes, Brca1 and p53, and inactivates the retinoblastoma (Rb) proteins in adult ovarian surface epithelial cells (KpB mouse model) (45, 46). Subsequently, KpB mice were subjected to a 60% caloriesderived from fat in a high fat diet (HFD) versus 10% calories from fat in a low fat diet (LFD) to induce diet-induced obesity (N=14/group) starting at 6 weeks of age and until sacrifice. After 8 months of exposure to the HFD or LFD, obese mice weighed significantly greater than non-obese mice (p=0.003, Table 1 ). There was no effect of HFD on non-fasted blood glucose levels or diabetes onset in KpB mice over the course of the diet (Table 1) . Body composition was significantly altered in obese KpB mice compared to non-obese controls. Percent body fat was six-fold greater in obese mice (Table 1, p=0.0001), while percent lean mass increased by 25% (p=0.0006, Table 1 ). The ovarian tumors were tripled in size in the obese mice as compared to non-obese mice (mean size of 3.7 cm 2 versus 1.2 cm 2 , Figure 1 , p=0.0065). This suggests that obesity can promote tumor progression in the KpB mouse model of ovarian cancer. 
*
Obesity was found to induce genomic differences between the obese and non-obese ovarian tumors. 439 genes were found to be significantly up-regulated (417 genes) or down-regulated (22 genes) in the ovarian tumors from obese KpB mice versus non-obese mice (FDR<0.2). Figure 2 is a heat map of 131 genes up-and down-regulated at a FDR<0.1. Many metabolically relevant genes were significantly upregulated in the ovarian tumors from the obese versus non-obese mice, such as lipocalin (2.7 fold), fatty acid amide hydrolase (2.7 fold), fatty acid 2-hydroxylase (2.2 fold), glycerol-3-phosphate acyltransferase (1.5 fold), protein phosphatase (1.2 fold), AMP deaminase 3 (1.6 fold), and protein kinase C (1.7 fold). Arginase 1 was the most upregulated gene (7.3 fold) and plays a role in the urea cycle, tissue remodeling and inflammation. Other upregulated genes identified in the ovarian tumors from the obese mice were related to cell adhesion, including neurotrimin (2.2 fold) and desmoglein 1-alpha (2.0 fold). Increased expression of histone 1 (2.3 fold) and endothelin-1 (5.8 fold) were also associated with obesity in the KpB mouse model. Another gene upregulated 3 fold was ectonucleoside triphosphate diphosphohydrolase. Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 was upregulated 6 fold and regulates heparan sulfate production which is involved in developmental processes, angiogenesis, blood coagulation and tumor metastasis. The serotonin transporter solute carrier family 6 member 4 (Slc6a4) was upregulated 5.4 fold by obesity. Important downregulated genes included spermidine synthase, an enzyme in spermidine synthesis and thrombospondin 4, an extracellular glycoprotein known to have roles in cellular migration, adhesion, attachment and proliferation. In the ovarian tumors from the obese versus nonobese mice, DAVID functional annotation analysis revealed significant enrichment in "phospoholipid binding" (EASE score of 0.008), "regulation of apoptosis" (EASE score of 0.014), "lipid binding" (EASE score of 0.015), "endopeptidase activity" (EASE score of 0.03) and "cell-cell signaling" (EASE score of 0.44) for those identified genes.
Metabolic differences were also found between the ovarian tumors from obese and non-obese KpB mice. Principle component analysis defined a clear separation between obese and non-obese. Differentiating metabolites were selected with the criteria of the variable importance in the projection (VIP) value>1 and p value (Student's t test) lower than 0.05. Twenty metabolites were identified using this criteria, all of which were upregulated in the ovarian tumors of the non-obese versus obese KpB mice (Table 2) .
Metabolites involved in inflammatory signaling and protein/collagen metabolism were down-regulated in the ovarian tumors of obese mice as compared to non-obese mice, including arginine (p=0.0268), Nglycylproline (p=0.0043) and 3-amino-2-piperidone (p=0.0099). Components and markers of oxidative stress were also downregulated in the tumors from obese mice: glutathione (p=0.0313), oxidized glutathione (p=0.0047), gluconolactone (p=0.0311) and 8-hydroxy-deoxyguanosine (p=0.0230). Lower levels of nucelotides (i.e. cytidine (p=0.0122 and p=0.0424), cytosine (p=0.0158), guanosine diphosphate (GDP, p=0.0404)) and adenosine monophosphate (AMP, p=0.0257) were detected with obesity. The serotonin metabolite, 5-hydroxyindoleacetic acid (5HIAA, p=0.0498), and the catecholamine metabolites, vanillactic acid (p=0.0079) and phenylethanolamine (p=0.0446), were found to be lower in the ovarian tumors of obese versus non-obese mice. Glutamate (p=.0318), N-acetylaspartic acid (p=0.0059) and succinic acid (p=0.0465) are involved in energy metabolism, and were decreased in the ovarian tumors of obese KpB mice as compared to their non-obese counterparts. LysoPC(16:1(9Z)) (p=0.0205), a lysophospholipid, and the metabolite of a toxic intermediate, inodxyl glucuronide (p=0.0439), were also lower in the ovarian tumors from obese animals. To further expand on this work, the KpB ovarian cancer mouse model was used to assess the tumor promoting effect of high fat diet (HFD)-diet-induced obesity on tumor initiation and promotion amongst different obesity exposures across the lifespan. KpB mice were placed on a LFD or a HFD at different time points during their lifespan, including in utero, adolescence and adulthood. Cross-over diet study design was employed to examine if weight loss by switching from a HFD to a LFD reverses elevated risk associated c Fold change with a value larger than 1 indicates a relatively higher concentration in tumors from non-obese (low fat diet-fed) KpB mice, while a value less than 1 means a relatively lower concentration as compared to tumors from obese (high fat dietfed) KpB mice.
e The metabolites were identified by in-house library (Std), NIST library (NIST) or HMBD database (HMDB). Table 3 . Diet Study using the KpB ovarian cancer mouse model to identify relevant windows of susceptibility to obesity-induced risk. The effect of obesity on tumor promotion in mice made obese by high fat diet versus non-obese mice at relevant periods of vulnerability including in utero, adolescence and adulthood as well as combinations of these exposures were explored.
Group
In utero exposure with obesity. Eight different diet exposures were examined, as depicted in Table 3 . Tumor weight (grams) was found to be larger when comparing group A (no exposure to a HFD; LFD in utero + adolescence + adulthood) to groups E (HFD in utero + adolescence + adulthood), F (HFD in utero + HFD in adolescence + LFD in adulthood) and H (HFD in utero + LFD in adolescence + HFD in adulthood) ( Figure 3A) . Tumor latency was found to be shorter when comparing group A (no exposure to a HFD; LFD in utero + adolescence + adulthood) to groups F (HFD in utero + HFD in adolescence + LFD in adulthood) and H (HFD in utero + LFD in adolescence + HFD in adulthood) ( Figure  3B ). Common to all the groups that had a statistically significant difference in either tumor weight or tumor latency compared to group A (no exposure to a HFD) was (1) in utero exposure to a HFD and (2) exposure to a HFD for at least two different timeframes across the lifespan of the mouse. This data is based on 6-8 mice per group; however, all of the data is not complete with an expected 12-15 mice per group at the completion of the study. This preliminary data does suggest that longer exposure to a HFD results in greater tumor weight and shorter tumor latency.
The weight of the mice was also greater in the groups with longer exposure to the HFD. When compared to group A (LFD in utero + adolescence + adulthood), groups B (LFD in utero + LFD in adolescence + HFD in adulthood), C (LFD in utero + HFD in adolescence + HFD in adulthood), E (HFD in utero + HFD in adolescence + HFD in adulthood) and H (HFD in utero + LFD in adolescence + HFD in adulthood) (Figure 4) . Common to all the groups that had a statistically significant difference in mouse weight compared to group A (no exposure to a HFD) was adulthood exposure to a HFD. There were no significant changes in blood glucose levels among the eight groups (data not shown). The ovarian tumors from each of these groups has been frozen for gene expression profiling and metabolomic comparative analysis in the upcoming year.
Task 2 (Aim 2):
To determine if PI3K/Akt/mTOR pathway hyperactivation and alterations in glucose metabolism are related to obesitydriven cancers in the KpB ovarian cancer mouse model.
We are waiting to sacrifice the rest of the KpB mice in each of the diet groups before we can proceed with this aim. As part of this aim, ovarian tumors from the KpB mice that were exposed to obesity initiated in utero versus adolescence versus adulthood versus combinations of these exposures will undergo Western immunoblotting and immunohistochemical analysis to assess for Table 3 for description of groups) (*p<0.05) Table 3 for description of groups) (*p<0.05) differences in the phosphorylated and/or total forms of the downstream target proteins of the IGF-1R and PI3K/Akt/mTOR pathway. A subset of these ovarian cancer tumors will be used for primary culture to assess for secretion of growth factors associated with ovarian carcinogenesis (i.e. IGF-1) and perturbations in glucose metabolism as evaluated by ELISA and metabolic assays, respectively.
Task 3 (Aim 3):
To assess cross-species differences of the gene expression profiles of ovarian cancer tumors from obese and non-obese women and KpB mice, using the relevant tumor data from The Cancer Genome Atlas (TCGA) Project database.
From the TCGA database, we collected expression measurements for 12,042 genes from the platform (BI_HT_HG-U133A level 3 data) for differential gene expression analysis among human serous OC samples. The detailed information of the data processing, quality control and normalization can be found on the TCGA website. To identify significantly differentially expressed genes associated with BMI, we applied linear modeling for responses as gene expression and covariates as 5 Tables 1 and 2 ). Genes that were down-regulated included the prolactin receptor (3.6 fold) and apolipoprotein B mRNA editing enzyme (3.1 fold), among others. Genes that were up-regulated included mitogenactivated protein kinase 1 (3.3 fold), phospholipid scramblase 1 (3.3 fold), carnitine/acylcarnitine translocase (3.2 fold), low density lipoprotein receptor-related protein 8 (apolipoprotein e receptor) (3.7 fold), apolipoprotein L3 (3.7 fold), apolipoprotein L1 (3.8 fold), lipoyltransferase 1 (4.2 fold), apolipoprotein L6 (4.2 fold) and the c-myc binding protein (4.1 fold). Many of these genes were related to the apolipoprotein pathway, particularly apolipoprotein L related genes. Apolipoprotein L genes are members of the high density lipoprotein family and play a central role in cholesterol transport. Multiple genes involving the Ras oncogene family were up-and down-regulated when comparing normal weight versus overweight/obese women, including ras responsive element binding protein 1, RAB5C, RREB1, ras-related GTP binding C, PAP1A, RAB7A, RAB31, RAB5A, and ras homolog family/member A. DAVID functional annotation analysis revealed significant enrichment in "protein transport" (Adjusted p-value for Benjamini = 5.5E-5), "antigen processing and presentation of exogenous peptide antigen" (Adjusted pvalue for Benjamini = 1.3E-3) and "pyrimidine ribonucleotide biosynthetic process" (Adjusted p-value for Benjamini = 3.6E-2) for these identified genes. Initially, we used the 347 genes with q-value < 0.1 to generate a heatmap, but the results of the hierarchical cluster analysis on these samples did not group them with a significantly different BMI distribution. Alternatively, we used the 175 genes with q-value < 0.05 to generate a heatmap, which is presented in Figure  5 , where the row signifies gene expression and the column is clustering according to BMI (BMI < 25 versus BMI ≥ 25). If we specified two groups to cut a tree resulting from the results of the hierarchical cluster analysis on the samples, the two clusters of samples had no statistically significant difference in the distribution of BMI. However, if we specified three groups to cut a tree resulting from the results of the hierarchical cluster analysis, there were two pairs of clusters of samples with a significantly different distribution of BMI. Specifically, the first pair of clusters of samples (cluster 1 versus cluster 2) had sample proportions of subjects with BMI ≥ 25 tumors that arose in KpB mice after adulthood exposure to a HFD versus a LFD, and many of these differences were related to metabolic relevant pathways.  Metabolically relevant alterations in gene expression were found with increasing BMI among human serous ovarian cancers, using the TCGA database. Mounting epidemiological and preclinical data suggest that metformin may be efficacious in endometrial cancer. However, two important questions that need to be addressed are: (1) Will metformin be universally effective in endometrial cancer or be more efficacious in the obese/insulin-resistant patient population? and (2) What role do transporters play in metformin uptake and action in the malignant endometrium? These fundamental questions will be explored in endometrial cancer, a disease driven by obesity and insulin resistance, using endometrial cancer mouse models and phase 0 and phase 2/3 clinical trials in endometrial cancer patients.
(2) American Cancer Society/Research Scholar Grant Obesity, Cation-Selective Transporters and Metformin in Endometrial Cancer Co-Principal Investigator: Bae-Jump 10% effort (1.2 calendar) Mounting epidemiological and preclinical data suggest that metformin may be efficacious in endometrial cancer. However, two important questions that need to be addressed are: (1) Will metformin be universally effective in endometrial cancer or be more efficacious in the obese/insulin-resistant patient population? and (2) What role do transporters play in metformin uptake and action in the malignant endometrium? These fundamental questions will be explored in endometrial cancer, a disease driven by obesity and insulin resistance, using endometrial cancer mouse models and phase 0 and phase 2/3 clinical trials in endometrial cancer patients.
CONCLUSION
Obesity is associated with increased risk and worse outcomes for OC, and alterations in PI3K/Akt/mTOR signaling may play a crucial role in this relationship with potential implications for prevention and improvement of outcomes for this disease. We and others have made significant progress investigating the effects of obesity on tumor cell growth, but an understanding of the interactions between obesity at specific vulnerable periods of development, OC and the PI3K/Akt/mTOR pathway is lacking. We theorize that the metabolic effects of obesity play a contributing role in the pathogenesis of OC and lead to phenotypically different cancers than those that arise in leaner women, potentially through hyperactivation of the mTOR kinase. We also posit that the timing and length of the obesity exposure is critical in the development of obesity-driven OCs. Although the PI3K/Akt/mTOR pathway is known to be separately important in obesity and OC, the complex interplay between both of these disease entities on PI3k/Akt/mTOR signaling in OC has not been simultaneously assessed. Our multi-dimensional approach is innovative because utilizes several tools including a unique genetically engineered mouse model (GEMM), cell lines and patient samples to comprehensively interrogate the obesity-induced carcinogenesis signature through molecular, biochemical, genomic and metabolomic analysis. While the PI3K/AKT/mTOR pathway is a likely candidate pathway, the defined approach will identify additional genes and metabolites heretofore underappreciated in OC that are dependent upon windows of obesity exposure.
To first study the connection between metabolic status and OC, we capitalized upon the novel K18-gT 121 +/-;p53 fl/fl ;Brca1 fl/fl (KpB) OC genetically engineered mouse model (GEMM) in the obesity-susceptible FVB/N background. KpB mice were used to investigate the impact of obesity on OC pathogenesis and to test the effects of varying the timing and length of the obesity exposure across the lifespan, including in utero, adolescence and adulthood. Adulthood exposure to obesity in the KpB mouse model accelerated tumorigenesis. A tripling of tumor mass was found in KpB mice fed a high fat obesogenic diet versus a low fat control diet in our initial pilot study. Gene expression and metabolomic profiling indicated statistically significant differences between the ovarian tumors from the obese versus non-obese mice, including metabolically relevant pathways.
We expanded on this work to assess which windows of exposure to obesity are most important for increased vulnerability and progression of OC. Eight different diet exposures were examined, as depicted in Table 3 . Longer exposure to a HFD resulted in greater tumor weight and shorter tumor latency, especially in diet exposures that included in utero exposure to obesity. The weight of the mice was also greater in the groups with longer exposure to a HFD, particularly those mice with adulthood exposure to a HFD. The ovarian tumors from each of these eight groups has been frozen for gene expression profiling and metabolomic comparative analysis as well as western blotting and immunohistochemical analysis for downstream targets of the PI3K/Akt/mTOR pathway. In the upcoming year, ovarian tumors from obese and non-obese mice will also be examined in primary culture as a means to interrogate the effects of the obesity exposure on mTOR hyperactivation and glucose metabolism, or pathways identified through genomics and metabolomics.
This proposal aims next to translate in vitro and preclinical studies into human relevance and explore the impact of obesity on human OC. Using The Cancer Genome Atlas (TCGA) database, we compared the gene expression between OCs from normal weight versus overweight/obese women. Metabolically relevant alterations in gene expression were found in relationship to BMI status among serous OCs, including multiple genes related to the apolipoprotein pathway. Apolipoproteins are proteins that bind lipids (oil-soluble substances such as fat and cholesterol) to form lipoproteins for transport through the lymphatic and circulatory systems. This will be pathway of interest for our future studies. In the upcoming year, cross-species gene expression comparisons of OC tumors derived from obese and non-obese women and KpB mice will be used as a strategy to identify obesity-dependent biomarkers and potential novel targets of treatment. Cross-species comparisons will lend strength to findings from either strategy, thus creating a powerful experimental paradigm. The proposed study design is innovative because the tools we will use such as the KpB mouse model and the TCGA database allows us to focus on the tumor/host interaction, especially in regards to obesity-driven effects. Through these complementary studies, we will advance the understanding of OC's metabolic and genomic responses to the tumor promoting environment of obesity and determine the impact of the timing and length of the obesity exposure on ovarian carcinogenesis.
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Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England journal of medicine. 2003;348 (17) Introduction Obesity has been linked to increased risk of many cancers, including breast, colon, endometrial, among others [1] . Currently, new cancer cases are in the order of 1.5 million with half a million cancer deaths per year, and nearly one in five are due to obesity [1, 2] . It is postulated that hyperglycemia and hyperinsulinemia resulting from overnutrition in obese patients provide abundant nutrients and growth factors to cancer cells, resulting in the ideal environment for tumor initiation and promotion [3] . Chronic inflammation and immunosuppression are also thought to be a link between obesity and cancer [3] . Contents lists available at ScienceDirect
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Epithelial ovarian cancer (OC) is one of the most deadly cancers with an overall 5-year survival of only 30-40%. Increasing evidence suggests that obesity is a significant risk factor for OC and associated with worse outcomes for this disease [1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Given the overall poor prognosis of OC and the rising rate of obesity, it is imperative to investigate obesity as a potential modifiable risk factor that may reverse risk and lead to the prevention and improvement of outcomes for OC. We hypothesize that the metabolic consequences of obesity may play a contributing role in the pathogenesis of OC and may lead to biologically and phenotypically different cancers than those that arise in normal weight women, possibly necessitating distinct treatment strategies. Herein, we assessed the impact of obesity on OC development and progression in a genetically engineered mouse model of serous OC and comprehensively interrogated the obesity-induced carcinogenesis signature through genomic and metabolomic analysis. Dyke, PhD, NIH) is a unique serous OC mouse model, wherein the tumor suppressor genes, Brca1 and p53 are specifically and somatically deleted and the retinoblastoma (Rb) proteins are inactivated in the adult ovarian surface epithelium [21] . Inactivation of all 3 Rb proteins by T 121 (a fragment of the SV40 large T antigen) is driven by the keratin 18 (K18) promoter [21] . Expression of the T 121 transgene and knockout of p53 and Brca1 are conditional and only activated via injection of an adenoviral vector expressing Cre (AdCre) into the ovarian bursa cavity of adult female mice. At approximately 6 months after AdCre injection, tumors develop in the affected ovary, while the un-injected ovary remains normal. All experimental animals were maintained in accordance with the Institutional Animal Care and Use Committee (IACUC) and the NIH guide for the Care and Use of Laboratory Animals. Recombinant adenovirus Ad5-CMV-Cre (AdCre) was purchased from the University of Iowa Transfer Vector Core at a titer of 10 11 -10 12 infectious particles/ml. To maximize weight gain, mice were provided a high-fat diet (HFD, obese group) (60% kcal from fat, Research Diets, New Brunswick, NJ) and control mice (non-obese group) were provided a low-fat diet (LFD) (10% kcal from fat, Research Diets, New Brunswick, NJ) ad libitum, beginning at 6 weeks of age. AdCre injection occurred at 8 weeks to induce OC 6 months later (at 8 months of age) [21] . Thirty-six hours following superovulation, the mice were anesthetized, and a single 1 cm incision was made on the dorsal surface of each mouse. The AdCre was then injected via a needle introduced into the oviduct near the infundibulum and into the ovarian bursa, and the incision was closed. All mice were sacrificed at 8 months of age. The primary outcome comparison between non-obese and obese mice was the response of tumor growth to the obesity exposure. This was assessed via direct measurement of the tumor at the time of sacrifice. At the time of sacrifice, the ovarian tumors were harvested, wet tumor weights recorded, and tissue was snap frozen in liquid nitrogen for later harvest of mRNA for microarray analysis and metabolites for metabolomic analysis.
Materials and methods

Obesity
Body weight & composition
Prior to starting mice on diet and weekly until sacrifice, body weight was measured. Body composition, including lean mass, fat mass, free water content and total water content, of non-anesthetized mice was also measured at pre-and post-diet exposures using the EchoMRI-100 quantitative magnetic resonance whole body composition analyzer (Echo Medical Systems, Houston, TX).
Blood glucose
Random blood glucose was measured prior to start of diet and at sacrifice using a Bayer Contour Blood Glucose Monitor (Bayer HealthCare LLC, Tarrytown, NY).
mRNA isolation
Approximately 25-50 mg of frozen OC tissue in small fragments was homogenized in RLT lysis buffer. Total RNA was isolated using the RNeasy mini kit and QIAshredder kit (Qiagen Inc., Mississauga, ON) following the manufacturer's instructions. RNA quantity and quality were analyzed by Nanodrop (Thermoscientific, Wilmington, DE).
Gene expression profiling
Microarrays were performed on ovarian tumors from non-obese and obese mice (N = 5/group) using Affymetrix GeneChip Mouse Genome 430 2.0 Arrays. These samples were processed in the Lineberger Comprehensive Cancer Center Genomics Core Facility. The image files were analyzed with GenePix Pro 4.1 and pre-processed via the UNC-Chapel Hill Microarray Database (https://genome.unc.edu) where a Lowess normalization procedure was performed to adjust for Cy3 and Cy5 channel biases [22] . In addition, probes with missing values in 3 or more samples in each of the obese and non-obese groups were removed. Two-class SAM (Significance Analysis of Microarrays, http://www-stat. stanford.edu/~tibs/SAM/) was performed to identify significantly differentially expressed genes using FDR b 0.2. EASE (Expression Analysis Systematic Explorer, http://david.niaid.nih.gov/david/ease.htm) analysis was used to interpret and identify biological themes (gene ontology categories) overrepresented in the gene list obtained from SAM results. The EASE Score was used as statistical measure of overrepresentation of a biological theme. Specifically, the EASE Score is a jackknifed one-tailed Fisher's exact probability which is calculated by removing one gene within the given category from the list and penalizes the statistical significance of categories supported by fewer genes; thus is a more robust measure than the Fisher's exact probability [23] .
Metabolomic profiling
Gas chromatography time-of-flight mass spectrometry (GC-TOFMS, Leco Corporation, St Joseph, MI) and liquid chromatography coupled with time-of-flight mass spectrometry (LC-TOFMS, Agilent Corporation, Santa Clara, CA) were used to analyze tumors from non-obese and obese mice (N = 5/group). Metabolite extraction followed previous publication with minor revision through the UNC/Nutrition Obesity Research Center (NORC) Core facility [24] . Briefly, 50 mg samples were extracted with 0.5 ml of methanol:chloroform:water = 3:1:1 (v:v:v) with homogenization for 3 min using 1-mm inner diameter balls in a Bullet Blender (Next Advance, Averill Park, NY). Two aliquots of 150 μl of supernatant were used for GC-TOFMS and LC-TOFMS analysis, separately. After removal of the extra supernatant, the remainder was extracted with 500 μl of methanol. Two aliquots of 150 μl of supernatant were combined into the tube containing first step extraction for GC and LC-TOFMS analysis, separately. Metabolite annotation was performed by comparing the mass spectrum and retention time to an inhouse library and NIST library (GC-TOMFS) or HMDB (LC-TOFMS) [25, 26] .
Statistical methods
Unpaired Student's t-test was used to determine statistical difference between non-obese and obese treatment groups using STATA software (College Station, TX). A p-value b0.05 was considered significant. For metabolomics, after normalization to the internal standard and sample weight, the data set was imported into SIMCA-p software
was first performed to check the outliers and the separation tendency (data not shown). A supervised orthogonal partial least squares-discriminant analysis (OPLS-DA) analysis was then performed. Differentiating metabolites were selected with the criteria of the variable importance in the projection (VIP) value N1 and p value (Student's t test) lower than 0.05.
Results
Obesity drove significant tumor progression in KpB mice
KpB mice were subjected to 60% calories-derived from fat in a high fat diet (HFD) versus 10% calories from fat in a low fat diet (LFD) to induce diet-induced obesity (N = 14/group) starting at 6 weeks of age and until sacrifice. After 8 months of exposure to the HFD or LFD, obese mice weighed significantly greater than non-obese mice (p = 0.003, Table 1 ). There was no effect of HFD on non-fasted blood glucose levels in KpB mice over the course of the diet (Table 1) . Body composition was significantly altered in obese KpB mice compared to non-obese controls. Percent body fat was six-fold greater in obese mice (Table 1 , p = 0.0001), while percent lean mass increased by 25% (p = 0.0006, Table 1 ). The ovarian tumors were tripled in size in the obese mice as compared to non-obese mice (mean size of 3. Obesity induces genomic differences between obese and non-obese ovarian tumors 439 genes were found to be significantly up-regulated (417 genes) or down-regulated (22 genes) in the ovarian tumors from obese KpB mice versus non-obese mice (FDR b 0.2, Supplemental Table 1 ). Fig. 2 is a heat map of 131 genes up-and down-regulated at a FDR b 0.1. Metabolically relevant genes were significantly upregulated in the ovarian tumors from the obese versus non-obese mice, such as lipocalin (2.7 fold), fatty acid amide hydrolase (2.7 fold), fatty acid 2-hydroxylase (2.2 fold), glycerol-3-phosphate acyltransferase (1.5 fold), protein phosphatase (1.2 fold), AMP deaminase 3 (1.6 fold), and protein kinase C (1.7 fold) (Supplemental Table 1 ). Arginase 1 was the most upregulated gene (7.3 fold) and plays a role in the urea cycle, tissue remodeling and inflammation. Other upregulated genes identified in the ovarian tumors from the obese mice were related to cell adhesion, including neurotrimin (2.2 fold) and desmoglein 1-alpha (2.0 fold). Increased expression of histone 1 (2.3 fold), endothelin-1 (5.8 fold), ectonucleoside triphosphate diphosphohydrolase (3 fold) and serotonin transporter solute carrier family 6 member 4 (Slc6a4) (5.4 fold) were also associated with obesity in the KpB mouse model. Significantly downregulated genes with obesity included spermidine synthase and thrombospondin 4.
In the ovarian tumors from the obese versus non-obese mice, EASE over-representation analysis revealed significant enrichment in "phospholipid binding" (EASE score of 0.008), "regulation of apoptosis" (EASE score of 0.014), "lipid binding" (EASE score of 0.015), "endopeptidase activity" (EASE score of 0.03) and "cell-cell signaling" (EASE score of 0.44) for those identified genes.
Metabolic differences between ovarian tumors from obese and non-obese KpB mice
Principle component analysis defined a clear separation between obese and non-obese samples (Fig. 3, 3 components, R2X = 0.563, R2Ycum = 0.95, Q2cum = 0.411). Differentiating metabolites were selected with the criteria of the variable importance in the projection (VIP) value N 1 and p value (Student's t test) lower than 0.05. Twenty metabolites were identified using this criterion, all of which were upregulated in the ovarian tumors of the non-obese versus obese KpB mice (Table 2) .
Metabolites involved in inflammatory signaling and protein/collagen metabolism were down-regulated in the ovarian tumors of obese mice as compared to non-obese mice, including arginine (p = 0.0268), Nglycylproline (p = 0.0043) and 3-amino-2-piperidone (p = 0.0099). 
Discussion
Recent evidence suggests that obesity may be a significant risk factor and associated with worse outcomes for OC [1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Therefore, a metabolic approach to the diagnosis and treatment of OC may provide a novel strategy to improve outcomes for this invariably lethal disease. Hence, we induced obesity in the KpB mouse, a faithful murine model of serous OC, to ask if obesity alters tumorigenesis. KpB mice fed a HFD had significant increases in their body weight and fat mass compared to mice fed a LFD. Herein, we report that obesity promoted tumor progression in the KpB mouse model of OC with a tripling of ovarian tumor size. Obesity has been associated with more rapid tumor growth in animal models of other cancer types, such as breast, colon and lung cancer [27, 28] , but this is the first study to demonstrate this for OC.
Genomic and metabolomic analyses were utilized to identify obesity-induced alterations in tumors with the intention of identifying significant pathways or biomarkers to aid in explaining why obese mice developed larger, more aggressive tumors. The metabolically relevant genes, lipocalin, ectonucleoside triphosphate diphosphohydrolase and fatty acid amide hydrolase, were upregulated in the ovarian tumors from the obese versus non-obese mice. Lipocalin, particularly lipocalin 2, has been previously found to be upregulated in number of different cancers, including OCs [29, 30] . The primary function of lipocalin is the transport of small ligands such as steroids, bilins, retinoids and lipids. In addition to its role in lipid transport, lipocalin has also been implicated in the inflammatory response. Another gene significantly upregulated was ectonucleoside triphosphate diphosphohydrolase, which is involved in the extracellular hydrolysis of ATP to generate adenosine, which signals through G-protein coupled receptors and regulates metabolic pathways and inflammation. Chronic inflammation is well known to play a role in obesity-driven cancers which could also explain the increased expression of both lipocalin and ectonucleoside triphosphate diphosphohydrolase in the ovarian tumors of obese KpB mice. Fatty acid amide hydrolase (FAAH) is a serine hydrolase that metabolizes N-acylethanolamines (i.e. N-arachidonoylethanolamine, N-oleoylethanolamine and N-palmitoylethanolamine), also known as endocannabinoids, to fatty acids plus ethanolamine. The endocannabinoid system is thought to be important in the regulation of cancer cell apoptosis, proliferation, migration, adhesion and invasion. Increased expression of the cannabinoid receptors (CB1R and CB2R) and FAAH has been documented in prostate and breast cancer and has been associated with worse outcomes [31] . FAAH inhibitors are under development for the treatment of pain and inflammation [31] , but may also be useful in cancer. Our data suggests that FAAH inhibitors might be a potential targeted agent for obesity-driven cancers.
Other unique, metabolically relevant genes that were associated with obesity and OC development in the KpB mouse model included fatty acid 2-hydroxylase, glycerol-3-phosphate acyltransferase, protein phosphatase, protein kinase C and AMP deaminase. Fatty acid 2-hydroxylase (FA2H) catalyzes the synthesis of 2-hydroxysphingolipids, a subset of sphingolipids that contain 2-hydroxy fatty acids. FA2H is thought to be involved in the cell differentiation of Schwann cells, keratinocytes and adipocytes. Glycerol-3-phosphate acyltransferase is an enzyme that participates in glycerolipid metabolism and glycerophospholipid metabolism. Protein phosphatases are essential to protein phosphorylation, an important form of reversible protein posttranslational modification involved in cell signaling cascades. The protein kinase C (PKC) family represents a number of protein kinase enzymes that are involved in regulating the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues on these proteins. The PKC family of enzymes has been implicated in the regulation of signal transduction, cell proliferation, metabolism and differentiation through its effects on regulation of the cell cycle. PKC inhibitors are already being evaluated in clinical trials for a variety of different cancers, including OC [32] . AMP deaminase 3 is a highly regulated enzyme that catalyzes the hydrolytic deamination of adenosine monophosphate to inosine monophosphate, a branch point in the adenylate catabolic pathway. AMP deaminase 3 is thought to be a potent regulator of energy metabolism in cells. Increased expression of AMP deaminases has been documented in hepatocellular carcinomas [33] but has not been explored in OC.
Although many metabolically relevant genes were found to be associated with obesity-driven cancers in the KpB mouse model, other upregulated genes and pathways were identified. This included genes related to cell adhesion, including neurotrimin and desmoglein 1-alpha. Expression of neurotrimin and desmoglein 1-alpha has not been previously documented in OCs. Increased expression of histone 1 in the ovarian tumors was also associated with obesity in the KpB mice. Histones are the chief protein component of chromatin and are critical for gene regulation. Endothelin-1 (ET-1) is a highly potent vasoconstrictive peptide and was found to be upregulated 5.8 fold in the ovarian tumors from obese mice. Overexpression of ET-1 has been implicated in the epithelial-mesenchymal transition, a mechanism by which transformed epithelial cells acquire the ability to proliferate, invade, resist apoptosis and metastasize [34] . In chemoresistant ovarian cancer cells, ET-1 has been found to be upregulated, leading to enhanced signaling through the MAPK and mTOR/Akt pathway, increased cell proliferation and reduced sensitivity to cisplatin and paclitaxel [35] . Endothelin receptor antagonists are being developed as potential chemotherapeutic agents for cancer [34] . In the ovarian tumors from the obese versus non-obese mice, DAVID functional annotation analysis revealed significant enrichment in "phospholipid binding", "regulation of apoptosis", "lipid binding", "endopeptidase activity" and "cell-cell signaling". Thus, the increase in aggressiveness, as manifested by a tripling of tumor size, in the obese KpB mice was accompanied by upregulation of genes involved in metabolic, apoptotic and cell signaling pathways.
Metabolic analysis revealed that 20 metabolites were identified as significantly regulated. In general, metabolomic analysis revealed that multiple metabolites contributed to separation of non-obese and obese mice with each metabolite being down-regulated in tumors derived from obese mice. Arginase 1 was the most up-regulated gene in obese tumors, which explains the lower detection of arginine concentrations. Catabolic disease states such as sepsis, injury and cancer cause an increase in arginine utilization, which can exceed normal body production, leading to arginine depletion. Arginase 1 converts L-arginine into L-ornithine and urea. Nitric oxide (NO) synthase and arginase compete for the same substrate (L-arginine); hence high arginase activity will blunt NO production, limiting potential pro-inflammatory responses necessary in tumoricidal immune responses. Indeed, arginase 1 is a marker of the M2, alternatively activated, macrophage that is often associated with more aggressive tumors [36] . Arginase also drives polyamine (such as spermidine) synthesis necessary for proliferation. Spermidine synthase in spermidine synthesis was a down-regulated gene in tumors from obese animals, perhaps in a negative feedback mechanism due to elevated delivery of ornithine generated by arginase 1 (30% lower levels of spermidine were detected in ovarian tumors of obese mice but this did not reach statistical significance). Ornithine can also be converted to the delta-lactam 3-amino-2-piperidine, and this was significantly blunted in tumors from obese mice. Finally, arginase generates ornithine which is used to generate proline (necessary for collagen synthesis) and glutamate/glutamine. Glutamate was found at lower levels suggesting that arginase was directing ornithine production to modulate collagen synthesis in tumors derived from obese mice. AMP and arginine both activate AMP kinase (AMPK) which stimulates substrate metabolism, while arginine can also activate mTOR [37, 38] . Decreased concentrations of both AMP and arginine in the ovarian tumors from obese versus nonobese mice may be a reflection of increased turnover of these metabolites in the rapidly growing tumors in the obese mice, and potential regulation of substrate metabolism.
N-glycylproline, which had the highest VIP contributing to separation between non-obese and obese tumors, was significantly lower in obese tumors relative to non-obese tumors in KpB mice ( Table 2 , p = 0.0043). N-glycylproline is an end product of collagen metabolism, but may be recycled into collagen synthesis, and this suggests a potential difference in tissue remodeling between nonobese and obese mice. Overall, Fig. 4 depicts metabolites and genes related to arginine/polyamine/collagen/glutamine metabolism that were decreased in the ovarian tumors from obese mice, suggesting that diet-induced alterations in the stromal components and extracellular matrix are associated with greater growth of the ovarian tumors in obese animals. Although glutathione disulfide (GSSG) and glutathione (GSH) were significantly regulated by diet, the ratio of the two (as an indicator of oxidative stress) was not significantly different between lean (0.5 −/+ 0.048) and obese (0.45 −/+ 0.284) tumors, suggesting that there was no active oxidative stress. However, a more stable marker of oxidative stress-induced DNA modification, 8-hydroxydeoxyguanosine, was detected at significantly lower concentrations in obese versus non-obese tumors. Lower concentrations of gluconolactone, an oxidized derivative of glucose, were also found in tumors from obese animals relative to lean, providing further evidence of changes in reduction-oxidation status between the ovarian tumors in the non-obese versus obese group. In sum, in ovarian tumors in obese KpB mice, there appears to be less DNA modification and markers of oxidized metabolites due to oxidative stress, suggesting that oxidative stress is not a major driver of obesity-driven tumorigenesis in the KpB mice or that compensatory mechanisms exist. Alternatively, it could be that the greater growth of ovarian tumors in the obese animals was driven by inflammatory cytokines produced in adipose tissue and distributed to the tumor through the circulation.
Lower concentrations of nucleotides (i.e. cytidine, cytosine, guanosine diphosphate (GDP), adenosine monophosphate (AMP)) may be reflective of increased cell turnover and alterations in utilization and production of these building blocks in the ovarian tumors from obese versus non-obese mice. We postulate that the observed heightened proliferation in the ovarian tumors from the obese versus non-obese mice, as evidenced by a tripling of tumor size, may result in the increased consumption of nucleotides. In the genomic analysis, we also found a 3-fold increase in ectonucleoside triphosphate diphosphohydrolase. This enzyme catalyzes the breakdown of multi-phosphated nucleotides (i.e. ATP, ADP, etc.) and removes free nucleotides and upstream compounds like AMP and GDP, all of which were significantly decreased in the ovarian tumors from the obese mice. In addition, low AMP detected in the ovarian tumors from obese mice suggests possible elevations in anabolic, ATP-burning processes such as lipid synthesis as well as protein, RNA and DNA synthesis.
5-Hydroxyindoleacetic acid (5HIAA) was significantly lower in obese versus non-obese tumors. 5HIAA is a breakdown product of serotonin. Interestingly, the serotonin transporter solute carrier family 6 member 4 (Slc6a4) was upregulated 5.4 fold by obesity. In addition to its function as a neurotransmitter in the central nervous system, increasing evidence suggests that peripheral serotonin may have proproliferative and anti-apoptotic effects and act as a mitogen in cancer cells [39, 40] ; hence, the obesity-mediated regulation of serotonin is of interest.
The catecholamine metabolites, vanillactic acid and phenylethanolamine, were lower in ovarian tumors derived from obese animals. Catecholamines, including epinephrine and norephinephrine, are known to regulate lipolysis [41] . Several studies report that catecholamine responses are blunted in obese versus non-obese individuals at rest and in response to physical activity, suggestive of decreased sympathetic nervous system activity [41] . A decrease in the catecholamine response in the obese mice could lead to reductions in lipolysis and an increase in fat stores that could be advantageous for cancer cell growth.
Succinic acid and glutamate were also significantly decreased by obesity in tumors ( Table 2 , p = 0.0465 and p = 0.0318). Succinate is a metabolite of the tricarboxylic acid cycle (TCA) cycle and an electron donor to complex II (Succinate-Q oxidoreductase) in oxidative metabolism. Glutamate is also the metabolic intermediate of glutaminolysis, which would feed into the TCA cycle upstream of succinic acid at alphaketoglutarate. Interestingly, fructose-6-phosphate did not reach statistical significance (non-obese vs. obese ratio 1.62, p = 0.0684) but contributed to principle component analysis variance (VIP was 1.67). Fructose 6-phosphate is an important intermediate in glycolysis. Taken together, low AMP, succinate, glutamate, and fructose 6-phosphate suggest that KpB tumors in obese mice have a substantially altered metabolic phenotype compared to tumors that have arisen in non-obese controls. We are currently investigating the role of glycolysis and oxidative metabolism, along with AMPK and mTOR signaling, in ovarian cancers from obese and non-obese patients.
Finally, cytidine is a precursor of cytodinetriphosphate, which is needed to create phosphatidylcholine (PC) and phosphatidylethanolamine. Interestingly, lysoPC(16:1(9Z)) was also downregulated in the ovarian tumors from obese versus non-obese mice. Lysophospholipids (LPLs) can play a role in signaling through G-protein coupled receptors, and are a readily accessible fat source for cancer cells [42] . LPLs are generated via inflammatory-responsive phospholipase A (PLA) activity, suggesting that there may be altered inflammatory signaling between non-obese and obese tumors, which is currently being explored. In our genomic analysis, significant enrichment was found in "phospholipid binding" in the ovarian tumors from the obese mice, potentially corresponding to increased utilization of lysophospholipids in the setting of obesity and depletion of cytidine and lysoPC.
In conclusion, we demonstrate that the obese state can promote tumor progression in the KpB mouse model of serous OC, resulting in genomic and metabolic differences between tumors arising in the obese versus non-obese state. Our work suggests that the metabolic consequences of obesity may be crucial in the pathogenesis of OC, resulting in biologically distinct cancers than those that arise in normal weight women. This may have important implications for the treatment of this disease, such that obesity status may be a critical factor in the individualization of management strategies. Further work will be focused on the investigation of the identified obesity-dependent metabolic biomarkers as well as potential novel targets of treatment that may be specific to obesity-driven OCs.
